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ABSTRACT
Introduction: NSCLC harboring activating mutations of EGFR is highly sensitive 
to first-line EGFR-tyrosine kinase inhibitors (TKIs), but drug resistance depending 
on the EGFR mutation p.T790M will occur in about 50-60% of patients. Detailed 
information on the amount of p.T790M plasmatic level associated with resistance 
to EGFR-TKIs and guidance to treatment with p.T790M-effective TKI depending on 
these levels, is lacking.
Methods: This study enrolled p.T790M-positive patients (n=49) affected by EGFR-
mutated NSCLC at progression to first-line EGFR-TKIs and, in selected cases (n=5), 
after second-line treatment with osimertinib. Cell-free circulating tumor DNA (cftDNA) 
was extracted from plasma and the quantitative analysis of EGFR ex19del, p.L858R 
and p.T790M was performed by digital droplet PCR.
Results: The mean amount of mutated alleles at progression to first-line EGFR-
TKIs was 108,492 copies/ml for ex19del, 97,336 copies/ml for p.L858R, but only 8,754 
copies/ml for p.T790M. There was no significant correlation between progression-
free survival and the ratio of p.T790M over EGFR activating mutations. The analysis 
of cftDNA in 5 patients treated with osimertinib revealed a marked decrease of all 
EGFR mutant alleles.
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Conclusions: The amount of p.T790M in plasma can be much lower than activating 
EGFR mutations. Despite this finding, osimertinib is effective in p.T790M-positive 
patients. These results indicate that clones driving resistance to EGFR-TKIs represent a 
minority among cells bearing activating EGFR-mutations. In addition, the identification of 
a threshold level of p.T790M is not a strict requirement for the selection of patients to be 
treated with osimertinib, since treatment showed a decrease in all EGFR mutated cells.
INTRODUCTION
Clonal heterogeneity of non-small cell lung cancer 
(NSCLC) has been well documented [1, 2] and contributes 
to the acquired resistance to targeted treatments [3-5]. 
Heterogeneity is a major challenge for the development of 
selective pharmacologic treatments. However, it remains 
unclear to which degree treatment outcome is affected by 
clonal evolution. There are multiple evidences that cells 
driving resistance in NSCLC are selected during treatment 
with EGFR-tyrosine kinase inhibitors (TKIs) [6]. Several 
mechanisms have been described, including the gatekeeper 
EGFR mutation p.T790M, MET amplification, and HER2 
mutations [6-9]. The missense p.T790M is the substitution 
of a threonine (T) with a methionine (M) in codon 790; 
it is found in approximately 50-60% of NSCLCs after 
progression to EGFR-TKIs [10] and is the principal 
biomarker of resistance to EGFR-TKIs [7, 11, 12]. The 
p.T790M mutation is located within the gatekeeper residue 
of EGFR; it increases the affinity of the receptor to ATP 
[7] and strongly reduces the pharmacologic activity of first 
generation EGFR-TKIs. This view is supported by the 
observation that introduction of vectors carrying p.T790M 
into cells confers gefitinib resistance [13]. Approximately 
0.32% to 78.95% of patients with NSCLC harboring 
EGFR activating mutations display p.T790M before 
administration of EGFR-TKI, although this percentage 
is variable according to test sensitivity [14]. As expected, 
subjects with a high p.T790M mutation burden had poorer 
clinical outcomes to EGFR-TKIs than patients with a low 
one [15]. It is therefore hypothesized that the selective 
pressure of EGFR-TKIs may select and favor the growth 
of p.T790M sub-clones, leading to acquired resistance.
Although data on pretreatment p.T790M [16] and 
at progression to first-line EGFR-TKI [11, 17-20] are 
available, the information on the relationship between 
p.T790M levels and activating EGFR mutation in patients 
progressing to first-generation EGFR-TKI are lacking. The 
availability of a minimally invasive approach based on 
the analysis of cell-free circulating tumor DNA in plasma 
(cftDNA) may represent a suitable approach to interrogate 
tumor heterogeneity by capturing DNA released from 
multiple tumor sites [4, 8] and may dynamically monitor 
the molecular evolution of drug resistance. Detection of 
p.T790M in combination with clinical signs of disease 
progression would represent a critical information to guide 
the administration of p.T790M-active drugs, including 
osimertinib that represents the new standard of care on 
this group of NSCLC patients [21, 22].
The aim of the present study was to document the 
relationship between plasma levels of activating EGFR 
mutations and p.T790M at the time of progression to first-
line EGFR TKIs in patients with NSCLC and provide 
initial information on the dynamics of cftDNA changes 
upon treatment with osimertinib.
The results show that the amount of p.T790M can 
be substantially lower than EGFR activating mutations in 
drug resistance setting. Despite this, patients may respond 
well to osimertinib, thus a threshold value (i.e., copies/ml) 
of p.T790M is not required for successful treatment with 
p.T790M-selective drug.
RESULTS
A total of 49 patients were enrolled in this study; 
their characteristics are summarized in Table 1. The 
median PFS of the first-line EGFR-TKI treatment was 
21 months (range 6-57 months). The activating mutations 
detected in cftDNA at the time of first-line EGFR-TKI 
progression were ex19del (42 subjects, 85.7%) and 
p.L858R (7 patients, 14.3%). The number of copies/mL 
of plasma of EGFR activating and p.T790M mutations 
are reported in Table 2; the median values of ex19del, 
p.L858R and p.T790M were 3,550 (range 130-3,390,000), 
420 (range 170-671,000) and 500 copies/mL (range 80-
194,000) respectively. The median value of the ratio 
p.T790M/EGFR activating mutations was 0.26 (range, 
0.0004-0.9) showing, overall, a low to very low ratio of 
p.T790M vs. activating mutations in patients at the time 
of progression to first/second-line EGFR-TKI (p<0,0001, 
Figure 1).
The statistical analysis of PFS vs. the ratio of 
p.T790M/EGFR activating mutations showed no 
significant difference (p = 0.075; Spearman’s rank 
correlation coefficient = 0.256) suggesting that previous 
EGFR-TKI does not influence the ratio p.T790M/EGFR 
and that a high ratio is not required to obtain resistance to 
treatment (Figure 2). No differences in mutation amounts 
were seen between fast and slow progressing patients 
comparing months of PFS.
The amount of ex19del, p.L858R and p.T790M 
EGFR mutant copies in plasma was monitored during 
treatment with osimertinib in 5 patients (2 with complete 
response to osimertinib, 2 with partial response and 1 with 
stable disease at first-tumor evaluation after 12 weeks) in 
order to gather information about the dynamics of EGFR 
mutational pattern as a function of therapy and time. The 
amount of EGFR mutant clones in plasma decreased in 
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Figure 1: Plasma levels of EGFR activating mutations (ex19del and p. L858R) and p.T790M at the moment of disease 
progression to first/second-generation EGFR-TKI. The analysis showed the very low ratio of p.T790M vs. activating mutations in 
patients at the time of progression to EGFR-TKI.
Table 1: Characteristics of patients
Characteristic Statistics
Nr. Patients 49
Age (years) 63 (42 - 81)
Sex
Male 16 (32.6%)
Female 33 (67.3%)
Smoking history
Former 20 (40.8%)
Never 29 (59.2%)
Stage
Stage IV 33 (67.3%)
Stage IIIb 16 (32.5%)
Prior TKIs
Gefitinib 31 (63.3%)
Erlotinib 14 (28.6%)
Afatinib 4 (8.2%)
Oncotarget86059www.impactjournals.com/oncotarget
parallel (ex19del and p.T790M or p.L858R and p.T790M), 
although the activity of osimertinib is higher on p.T790M 
than ex19del and p.L858R and it would be, therefore, 
expected a steeper decline of p.T790M than ex19del and 
p.L858R. In general, the reduction of both ex19del and 
p.T790M was more marked than in the single patient 
bearing both p.T790M and p.L858R, which persisted 
in plasma (Figure 3). The decrease of mutated alleles in 
plasma was maintained during response to treatment.
DISCUSSION
The EGFR gatekeeper mutation p.T790M confers 
resistance to first- and second- generation EGFR-TKIs 
and prolongs the biologic condition of tumor addiction to 
EGFR transduction pathway in these tumors. Therefore, 
the development of new drugs with improved targeting 
capability of EGFR activating mutations and with 
extended spectrum to p.T790M is an active area of 
research [23, 24]. Osimertinib is the first drug approved 
for the treatment of p.T790M-positive NSCLC after 
failure of first/second generation EGFR TKIs [21, 22].
Detection of mutant alleles can be performed 
in tissue as well as plasma, and ddPCR is a sensitive 
technology suitable for cftDNA detection and analysis 
[25]. Indeed, our previous work demonstrated that ddPCR 
detection of p.T790M in plasma reached a meaningful 
sensitivity of 81.8% and a specificity of 85.7%; in 
addition, the overall concordance between plasma and 
tissue analysis was good and corresponded to 83.3% [8].
Although the detection of p.T790M in EGFR-
mutant NSCLC patients can be performed on both plasma 
and tumor tissue, the evolution of diagnostic approaches 
towards minimally-invasive procedures such as cftDNA 
is desirable for a number of reasons, including a) the 
invasive character of a tissue biopsy, b) unreachable 
tumor sites or insufficient tissue obtained after biopsy 
[26] and c) limitation of tissue biopsy in capturing tumor 
heterogeneity due to the small amount of tissue collected 
and number of tumor sites sampled. Indeed, ESMO 
clinical practice guidelines for diagnosis, treatment 
and follow-up of patients with NSCLC reports that if 
the p.T790M in peripheral blood is observed, treatment 
with third-generation EGFR TKIs is justified, while it 
recommends rebiopsy if cftDNA is negative for p.T790M 
[27]. Timely analysis of biomarkers to guide treatment 
decision is crucial and any delay in obtaining molecular 
testing results can postpone treatment decisions and 
reduce effectiveness of therapy for patients with advanced 
NSCLC [28].
p.T790M can be detected in plasma at a median 
time of 2.2 months prior to disease progression and is a 
predictive factor of resistance and disease outcome [29]. 
The role of p.T790M may change, depending on disease 
stage/phase. In particular, patients positive for p.T790M 
before treatment with EGFR-TKI show significantly 
inferior PFS (8.9 vs. 12.1 months) and overall survival 
(19.3 vs. 31.9 months) compared with those without 
p.T790M [30]. On contrary, at the time of disease 
progression after first- and second- generation EGFR-TKI, 
the presence of EGFR p.T790M is a favourable prognostic 
marker independently from the treatment with osimertinib 
[11]. Patients with p.T790M had a significantly longer 
post-progression survival, while subjects without p.T790M 
more often progressed in a previously uninvolved organ 
system and exhibited a poorer performance status at time 
of progression [11].
p.T790M shows a complex biological behaviour, 
since p.T790M status in patients may change both 
temporally and spatially among tumor sites at least in 
part due to the selective pressure from EGFR-TKI [31]. 
Interestingly, p.T790M status of NSCLC varies after 
EGFR-TKI discontinuation and may change from positive 
to negative, thus justifying a potential re-challenge with 
EGFR-TKI [31]. It is not surprising that after further 
EGFR-TKI administration, p.T790M status may change 
from negative to positive again [31]. Previous work 
provided initial evidence of the different amounts of 
p.T790M vs. activating mutations in plasma samples in 
9 patients [32]. In addition, a recent report suggested a 
possible clinical importance for detection of p.T790M at 
low levels in plasma samples [18]. Longitudinal cftDNA 
analysis revealed an increase in plasma EGFR-activating 
mutation, and p.T790M announced rociletinib resistance 
in some patients, whereas in others the activating mutation 
increased but p.T790M remained suppressed [20]. These 
findings demonstrate the role of tumor heterogeneity when 
drugs targeting a single resistance mechanism are given 
to patients [20]. Based on the results of the present study, 
it would be interesting to evaluate the effectiveness of 
combination regimens that also target p.T790–wild-type 
clones. The present work shows that patients progressing 
to first/second-generation EGFR-TKIs displayed a low 
amount of p.T790M compared to the EGFR activating 
mutations.
On the basis of the cftDNA data of the present work 
it can be speculated that either EGFR amplification could 
be a frequent finding in these patients, or that p.T790M is 
present in a minority of cells of the tumor cell population 
after TKI failure or both. Therefore, the intriguing 
questions are: 1) how frequent is EGFR amplification 
in these patients, 2) how p.T790M can drive tumor 
progression being so low within the tumor; 3) is there 
another mechanism of resistance in addition to p.T790M, 
and 4) is p.T790M able to synergize with activating EGFR 
mutation.
Our data indicate that, even in presence of low 
amount of p.T790M, tumors respond to the third-
generation TKI osimertinib, which is mainly active 
against p.T790M. The drug shows higher activity 
against the EGFR double mutants ex19del/p.T790M and 
p.L858R/p.T790M with respect to the EGFR bearing 
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Table 2: Plasma levels of EGFR activating mutations and p.T790M
Patient Mutation Activating mutation 
(copies/ml)
p.T790M 
(copies/ml)
p.T790M/activating 
mutation ratio
Lines of 
treatment
PFS to EGFR-
TKIs (months)
1 ex19del 333,000 194,000 0.58 1 16
2 ex19del 3,400 300 0.09 1 15
3 ex19del 1,200 190 0.16 1 35
4 ex19del 5,900 900 0.15 2 25
5 ex19del 160 80 0.5 1 12
6 ex19del 3,200 800 0.25 1 13
7 ex19del 570 500 0.87 2 27
8 ex19del 310 190 0.61 2 20
9 ex19del 1,500 270 0.18 1 12
10 ex19del 13,000 700 0.05 1 17
11 ex19del 420 80 0.19 2 23
12 ex19del 6,400 410 0.06 1 19
13 ex19del 410 80 0.19 2 11
14 ex19del 2,500 1,000 0.4 1 32
15 ex19del 700 180 0.26 3 57
16 ex19del 3,900 700 0.18 1 11
17 ex19del 32,600 14,500 0.44 2 19
18 ex19del 150 90 0.6 3 41
19 ex19del 6,900 2,100 0.3 1 23
20 ex19del 275,000 47,200 0.17 1 28
21 ex19del 54,000 4,000 0.07 1 7
22 ex19del 82,000 56,400 0.69 2 22
23 ex19del 32,100 5,800 0.18 1 13
24 ex19del 5,700 1,100 0.19 2 48
25 ex19del 130 110 0.85 1 17
26 ex19del 1,000 280 0.28 2 32
27 ex19del 44,200 11,000 0.25 1 30
28 ex19del 250 160 0.64 1 19
29 ex19del 270 140 0.52 2 28
30 ex19del 800 480 0.6 2 36
31 ex19del 3,390,000 5,200 0.0015 1 11
32 ex19del 3,700 90 0.02 1 13
33 ex19del 8,200 2,100 0.26 1 36
34 ex19del 44,400 110 0.002 1 10
35 ex19del 1,200 210 0.18 1 21
36 ex19del 3,200 1,100 0.34 1 18
(Continued)
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Patient Mutation Activating mutation 
(copies/ml)
p.T790M 
(copies/ml)
p.T790M/activating 
mutation ratio
Lines of 
treatment
PFS to EGFR-
TKIs (months)
37 ex19del 3,300 1,500 0.45 1 15
38 ex19del 1,400 300 0.21 1 6
39 ex19del 8,300 2,700 0.32 1 13
40 ex19del 62,000 11,000 0.17 2 10
41 ex19del 17,300 11,100 0.64 1 14
42 ex19del 102,000 43,900 0.43 1 12
43 L858R 4,120 620 0.15 2 17
44 L858R 420 170 0.4 1 10
45 L858R 400 90 0.23 2 10
46 L858R 4,900 4,400 0.9 1 11
47 L858R 170 80 0.48 1 18
48 L858R 671,000 290 0.0004 1 13
49 L858R 340 270 0.8 2 20
Median (range) 3,400 (130-
3,390,000)
500 (80-
194,000)
0.26 (0.0004-0.9) 17 (6-57)
Figure 2: Absence of correlation between p. T790M/activating mutation ratio and PFS to first/second-generation 
EGFR-TKI, highlighting that a high ratio is not required to obtain resistance to treatment, but also very low amounts 
drive the resistance.
Oncotarget86062www.impactjournals.com/oncotarget
Figure 3: Decreasing of mutated EGFR alleles (ex19del, p. L858R, p.T790M) in plasma during treatment with 
osimertinib. The amount of EGFR mutant clones in plasma rapidly decreased in parallel and was maintained during treatment, accordingly 
to the tumor response.
Oncotarget86063www.impactjournals.com/oncotarget
only the activating mutation as demonstrated by in vitro 
experiments. In particular, mean IC50 values are 17 and 
4 nM for the ex19del and the p.L858R, respectively and 
13 and 5 nM for the double mutants ex19del+p.T790M 
and p.L858R+p.T790M, respectively [6]. These data are 
confirmed also in patients of the present study because by 
monitoring the amount of residual EGFR mutations during 
osimertinib treatment, it is clear that cell clones carrying 
the double mutant ex19del/p.T790M or p.L858R/p.T790M 
and clones with the ex19del alone drastically decrease 
in their amount, while cell clones carrying the p.L858R 
alone remain detectable because of the low potency of 
osimertinib against this mutation.
In patients monitored during osimertinib treatment, 
p.T790M reduction was marked and similar to the 
decline of plasma levels of EGFR activating mutations. 
The differences in concentration between them and the 
p.T790M may confirm that the tumor is heterogeneous, 
and it is composed by 1) wild-type clones, 2) cells carrying 
both the EGFR activating and p.T790M mutations, 3) 
clones with only the original EGFR activating mutation. 
A distinct population of cells with the p.T790M only is 
unlikely to be present.
In conclusion, the present work demonstrates the 
feasibility of detecting very low amounts of p.T790M 
in plasma by a sensitive analytical approach and that 
this mutation is associated with tumor progression – 
and response to osimertinib – even though it may be a 
minority with respect to ex19del and p.L858R activating 
mutations. Further studies are warranted to gain additional 
knowledge on the interaction between EGFR mutations 
in TKI-resistant NSCLC, and to determine the clinical 
consequences to be connected to cftDNA outcomes in 
plasma. However, nowadays, is often required a treatment 
adaptation based on pharmacogenetic data [33, 34], and 
these results provide strong evidence supporting the 
usefulness of cftDNA as a good predictive biomarker.
MATERIALS AND METHODS
The present study included 49 NSCLC patients 
carrying the p.T790M mutation in cftDNA. These patients 
were consecutively enrolled between June and October 
2016 from a population of subjects with the following 
characteristics: 1) stage IIIb/IV disease carrying EGFR 
activating mutations (exon 19 deletions [ex19del] and/or 
exon 21 p.L858R) in tumor tissue at the time of initial 
diagnosis; 2) treatment with first- or second-generation 
EGFR-TKIs (gefitinib/erlotinib/afatinib), as per approved 
indication and 3) clinical and imaging evidence of disease 
progression, as per standard practice.
In order to detect EGFR ex19del, p.L858R and 
p.T790M mutations, one blood sample was taken in each 
patient at the time of disease progression; in 5 subjects 
(enrolled in ASTRIS Trial [35]), 2 to 4 additional blood 
drawings were obtained to monitor EGFR ex19del, 
p.L858R and p.T790M mutations during osimertinib 
administration.
Blood was sampled as per routine biochemistry 
testing, collected in EDTA tubes and centrifuged at 4°C 
for 10 min at 3000 rpm within two hours after drawing. 
Plasma samples (2 ml) were taken from material to be 
discarded and stored at −80°C until analysis. Circulating 
tumor DNA was extracted using the QIAmp Circulating 
Nucleic Acid Kit (Qiagen®, Valencia, CA, USA) 
following the manufacturer’s protocol. The ex19del, 
p.L858R and p.T790M alleles were examined using a 
digital droplet PCR (QX100™ Droplet Digital™ PCR 
System, BioRad®, Hercules, CA, USA) as previously 
described [8]. Droplets with a fluorescence intensity 
threshold higher than 3,000 were considered positive for 
the presence of mutations and results were given as copies 
of allele/ml.
This study was compliant with local ethical 
practices; in particular, patients received treatments as per 
approved drug label and molecular tests were performed 
on residual material from standard diagnostic procedures.
Statistical analysis
Progression-free survival (PFS) was calculated 
from the first day of first-line EGFR-TKI treatment to 
radiological evidence of disease progression according 
to RECIST criteria; deaths for other causes than disease 
progression were considered events [36]. PFS of patients 
receiving osimertinib was not considered for statistical 
analysis.
Before inferential statistics, an exploration phase 
was performed using box plots and scatter plots. We 
assessed three main quantitative factors: 1) concentration 
of the activating mutations (ex19del, p.L858R), 2) levels of 
p.T790M, and 3) their ratio (resistant/activating). In order 
to verify if the quantitative data were normally distributed 
we used the Kolmogorov–Smirnov and Shapiro–Wilks 
tests. A comparison between the three factors and PFS (all 
patients relapsed to first-line EGFR-TKI) was performed 
by a nonparametric correlation analysis (Spearman’s rank 
correlation coefficient), whereas Kruskal–Wallis and 
Mann–Whitney (two-tailed) tests were used to perform 
comparisons among the factor associated to the different 
treatment lines. Finally, the Wilcoxon test (two-tailed) 
has been performed to compare the number of copies/ml 
of plasmatic EGFR activating and p.T790M mutations. 
A p<0.05 was considered as statistically significant; all 
statistical analyses were performed using the SPSS version 
24 software.
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